Enadenotucirev clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses enadenotucirev is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Enadenotucirev
- 4
Studies by the year they started
5 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Akamis Bio (4) · University of Oxford (1)
Studies
Open first, then newest update. How each study uses enadenotucirev is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal CancerCompletedPhase 1University of OxfordNCT03916510Written as EnadenotucirevHow we know
- Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsCompletedPhase 1Akamis BioNCT02636036Written as enadenotucirevHow we know
- Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer PatientsCompletedPhase 1Akamis BioNCT02028117Written as EnadenotucirevHow we know
- Mechanism of Action Trial of ColoAd1CompletedPhase 1Akamis BioNCT02053220Written as Colo-Ad1How we know
- Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer PatientsCompletedPhase 1/2Akamis BioNCT02028442Written as EnadenotucirevHow we know
Codes
What other systems call enadenotucirev · ClinicalTrials.gg INT001193
- MeSH (NLM) C000654204enadenotucirevOne source NLM
- UNII (FDA) KX7ZYR6OQWENADENOTUCIREVConfirmed FDA, NLM
- NCI Thesaurus C113786EnadenotucirevOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654204 | enadenotucirev | One source NLM |
| UNII (FDA) | KX7ZYR6OQW | ENADENOTUCIREV | Confirmed FDA, NLM |
| NCI Thesaurus | C113786 | Enadenotucirev | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.